Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CNTA

Centessa Pharmaceuticals plc ADR

Apr 28 • 04:00PM ET

39.46

-0.05 -0.13 %

Healthcare • Biotechnology • United Kingdom • Mid • NASD

Peers: VRTX REGN MRNA BMRN IONS ALNY SRPT NBIX INCY ZLAB

| Held by: IBB SPDW FFSM ONEQ BBC MRGR ISCF IBBQ IBRN BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.46	Insider Own	35.58%	Shs Outstand	149.23M	Perf Week	-0.08%
Market Cap	5.89B	Forward P/E	-	EPS next Y	-1.80	Insider Trans	-0.89%	Shs Float	96.13M	Perf Month	37.49%
Enterprise Value	5.71B	PEG	-	EPS next Q	-0.38	Inst Own	67.19%	Short Float	3.61%	Perf Quarter	51.83%
Income	-197.82M	P/S	391.01	EPS this Y	-15.91%	Inst Trans	7.20%	Short Ratio	1.33	Perf Half Y	63.40%
Sales	15.06M	P/B	11.18	EPS next Y	-6.52%	ROA	-31.16%	Short Interest	3.47M	Perf YTD	57.78%
Book/sh	3.53	P/C	19.99	EPS next 5Y	3.26%	ROE	-42.61%	52W High	40.26 -1.99%	Perf Year	186.98%
Cash/sh	1.97	P/FCF	-	EPS past 3/5Y	14.25% -130.75%	ROIC	-30.69%	52W Low	10.95 260.37%	Perf 3Y	736.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.87%	Volatility	0.26% 0.96%	Perf 5Y	-
Dividend TTM	-	EV/Sales	379.31	EPS Y/Y TTM	26.67%	Oper. Margin	-1381.71%	ATR (14)	0.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.57	Sales Y/Y TTM	117.83%	Profit Margin	-1313.74%	RSI (14)	73.36	Recom	2.67
Dividend Gr. 3/5Y	- -	Current Ratio	8.57	EPS Q/Q	43.53%	SMA20	-0.30%	Beta	1.16	Target Price	45.22
Payout	-	Debt/Eq	0.22	Sales Q/Q	-	SMA50	23.32%	Rel Volume	0.43	Prev Close	39.51
Employees	118	LT Debt/Eq	0.22	Earnings	Mar 26	SMA200	59.13%	Avg Volume	2.61M	Price	39.46
IPO	May 28, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.42% -100.00%	Trades		Volume	1,120,750	Change	-0.13%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Downgrade	Truist	Buy → Hold	$38
Feb-24-26	Initiated	Wolfe Research	Outperform	$40
Dec-10-25	Resumed	Oppenheimer	Outperform	$62
Oct-28-25	Initiated	Stephens	Overweight	$35
Sep-03-25	Initiated	Wells Fargo	Overweight	$31
Aug-29-25	Resumed	Oppenheimer	Outperform	$40
Jul-21-25	Initiated	Truist	Buy	$30
May-28-25	Initiated	Needham	Buy	$35
May-08-25	Initiated	Chardan Capital Markets	Buy	$30
Mar-31-25	Initiated	Piper Sandler	Overweight	$38
Jan-07-25	Initiated	TD Cowen	Buy
Sep-20-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$11 → $26
Sep-19-24	Initiated	B. Riley Securities	Buy	$33
Jul-18-24	Initiated	Oppenheimer	Outperform	$14
Nov-15-23	Upgrade	Jefferies	Hold → Buy	$4 → $11
Oct-26-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$4 → $8
Jun-21-23	Initiated	Evercore ISI	Outperform
Jun-12-23	Initiated	Guggenheim	Buy	$9
Mar-17-23	Initiated	SVB Securities	Outperform	$6
Aug-12-22	Downgrade	Morgan Stanley	Overweight → Underweight	$10 → $5

Show Previous Ratings

Apr-20-26 04:33PM	Are CNTA, KORE, CWAN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-10-26 01:34PM	Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-07-26 02:48PM	Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-01-26 09:46AM	Disney upgraded, Nike downgraded: Wall Street's top analyst calls (The Fly)
06:48AM	Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa (Pharmaceutical Technology)
08:00PM	Loading…
Mar-31-26 08:00PM	The Year Is Off to the Strongest Start for Big Deals Ever (The Wall Street Journal) +44.02%
05:46PM	Big Drug Companies Hunting for Deals Are Lowering Their Sights (The Wall Street Journal)
04:25PM	Eli Lilly to Acquire Centessa in Up to $7.8 Billion Deal, 70% Premium (GuruFocus.com)
04:18PM	Dow closes with biggest daily gain in months amid hopes for Middle East peace (Proactive)
03:40PM	Options Traders Pick Up Pharma Stock After Eli Lilly Buyout (Schaeffer's Research)
02:43PM	Nasdaq shoots higher, Dow adds momentum as Trump looks for end to war (Proactive)
11:38AM	Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? (PR Newswire)
11:26AM	Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio (Proactive)
09:47AM	Stocks to Watch Tuesday: McCormick, Unilever, Marvell, Centessa, Apellis (The Wall Street Journal)
09:25AM	Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares Skyrocket (Investor's Business Daily)
08:32AM	Loading…
08:32AM	Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug (MarketWatch)
07:48AM	Centessa shares surge after Lilly unveils $6.3 billion takeover deal (Investing.com)
07:18AM	Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion (The Wall Street Journal)
06:45AM	Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (PR Newswire)
Mar-08-26 03:11PM	Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference (MarketBeat)
Feb-16-26 12:23PM	Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA) (Insider Monkey)
Feb-13-26 05:12AM	Centessa Pharmaceuticals CEO Teases Transformational 2026 as ORX750 Nears Registrational Trials (MarketBeat)
Feb-03-26 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-14-26 05:00PM	Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting (GlobeNewswire)
Jan-12-26 10:11AM	Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis (Insider Monkey)
Jan-08-26 09:12AM	Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal (Insider Monkey)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 07:00AM	Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications (GlobeNewswire) -8.08%
Dec-09-25 12:20AM	Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results (Insider Monkey)
Dec-05-25 06:35PM	Ashland, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
01:25PM	Loading…
Nov-13-25 01:25PM	Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program (Insider Monkey)
Nov-12-25 06:27PM	Why Centessa Pharmaceuticals Stock Crushed the Market Today (Motley Fool) +18.46%
Nov-11-25 08:40PM	Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares (GlobeNewswire)
04:00PM	Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares (GlobeNewswire)
Nov-07-25 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-25 01:58PM	Centessas stock recovers from drop on sleep drug data (Clinical Trials Arena)
Nov-05-25 07:00AM	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program (GlobeNewswire) -5.14%
Oct-28-25 09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
Sep-15-25 09:09AM	LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data (Insider Monkey)
Sep-03-25 07:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire) -7.87%
Aug-29-25 09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Aug-12-25 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 (GlobeNewswire)
Jul-21-25 04:12PM	Why Alkermes Tumbled On Its Positive Narcolepsy Study (Investor's Business Daily)
01:35PM	Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. (Investor's Business Daily)
Jul-15-25 08:58AM	Centessa Pharmaceuticals Advances Neurological Drug ORX142 to Clinical Trials (Insider Monkey)
Jul-04-25 03:00AM	Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist (GlobeNewswire)
Jun-24-25 12:46PM	Centessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 Study (Insider Monkey) +9.23%
Jun-17-25 09:05AM	Centessa announces clearance of IND for ORX142 (TipRanks)
Jun-16-25 12:00PM	Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:00AM	Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year (GlobeNewswire)
Jun-04-25 09:55AM	Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet (Zacks) -6.21%
May-19-25 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 (GlobeNewswire)
May-09-25 12:01PM	Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz (TipRanks)
May-05-25 07:59AM	Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
Apr-03-25 04:08PM	Centessa Pharmaceuticals: Smooth Move To New Programs, But Questions Remain (Seeking Alpha) -10.57%
Mar-24-25 07:00AM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 (GlobeNewswire) +5.59%
Mar-06-25 04:14PM	Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Jan-28-25 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-13-25 09:51AM	Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20? (Insider Monkey)
Jan-09-25 05:14PM	Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25? (Insider Monkey)
Jan-08-25 07:05AM	Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer (GlobeNewswire) -7.04%
Dec-20-24 10:31AM	Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday? (Insider Monkey)
Nov-13-24 06:15AM	Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing (BioPharma Dive) +6.35%
Nov-12-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update (GlobeNewswire)
Nov-04-24 07:30AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-12-24 10:18AM	Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech (Insider Monkey)
Oct-09-24 08:04AM	Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments (Insider Monkey)
Sep-26-24 06:00AM	Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Sep-12-24 10:34PM	Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares (GlobeNewswire) +9.82% +12.52%
Sep-11-24 04:04PM	Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares (GlobeNewswire) -5.69%
Sep-10-24 04:34PM	Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
12:19PM	Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers (Benzinga)
11:18AM	Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
08:15AM	Investors are waking up to Centessas sleepiness drug (BioPharma Dive)
07:00AM	Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers (GlobeNewswire)
Aug-27-24 08:00AM	Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Aug-24-24 01:18AM	Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ... (GuruFocus.com)
Aug-21-24 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade (Zacks)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-10-24 07:00AM	Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer (GlobeNewswire)
May-28-24 09:35AM	Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA) (Zacks)
May-21-24 08:45AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-13-24 09:54PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 (GlobeNewswire)
Apr-24-24 04:47AM	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS (MT Newswires)
Apr-23-24 09:36PM	Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares (GlobeNewswire) -6.00%
06:00PM	Centessa Pharmaceuticals Eyes $100 Million in ADS Offering (MT Newswires)
04:17PM	Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares (GlobeNewswire)
Apr-22-24 07:00AM	Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 (GlobeNewswire) -5.39%
Mar-28-24 11:53PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
06:11PM	Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results (GuruFocus.com)
04:28PM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 (GlobeNewswire)
Mar-27-24 01:26AM	Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares (GuruFocus.com)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace) +5.18%
Feb-22-24 08:00AM	Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 07:00AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire) +24.13%
Jan-22-24 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Karen M.	Chief People Officer	Mar 26 '26	Option Exercise	8.01	41,076	329,019	103,161	Mar 27 06:17 PM
Anderson Karen M.	Chief People Officer	Mar 26 '26	Sale	30.12	41,076	1,237,382	62,085	Mar 27 06:17 PM
Weinhoff Gregory M	Chief Business Officer	Mar 26 '26	Option Exercise	3.85	23,998	92,392	89,923	Mar 26 08:36 PM
Weinhoff Gregory M	Chief Business Officer	Mar 26 '26	Sale	30.00	23,998	719,940	65,925	Mar 26 08:36 PM
Weinhoff Gregory M	Officer	Mar 26 '26	Proposed Sale	28.15	23,998	675,544		Mar 26 04:22 PM
Anderson Karen M.	Officer	Mar 26 '26	Proposed Sale	28.15	41,076	1,156,289		Mar 26 04:05 PM
Anderson Karen M.	Chief People Officer	Mar 16 '26	Option Exercise	4.01	64,768	259,720	126,853	Mar 18 06:43 PM
Anderson Karen M.	Chief People Officer	Mar 17 '26	Option Exercise	4.01	10,043	40,272	72,128	Mar 18 06:43 PM
Anderson Karen M.	Chief People Officer	Mar 16 '26	Sale	28.21	64,768	1,826,969	62,085	Mar 18 06:43 PM
Anderson Karen M.	Chief People Officer	Mar 17 '26	Sale	28.10	10,043	282,210	62,085	Mar 18 06:43 PM
Anderson Karen M.	Officer	Mar 17 '26	Proposed Sale	27.98	10,043	281,003		Mar 17 04:02 PM
Anderson Karen M.	Officer	Mar 16 '26	Proposed Sale	28.21	64,768	1,826,969		Mar 16 04:24 PM
Anderson Karen M.	Chief People Officer	Mar 13 '26	Option Exercise	4.01	109,398	438,686	182,114	Mar 13 06:23 PM
Anderson Karen M.	Chief People Officer	Mar 13 '26	Sale	26.25	120,029	3,150,673	62,085	Mar 13 06:23 PM
Weinhoff Gregory M	Chief Business Officer	Mar 13 '26	Sale	26.33	73,196	1,927,131	65,925	Mar 13 06:22 PM
Anderson Karen M.	Officer	Mar 13 '26	Proposed Sale	25.86	120,029	3,103,950		Mar 13 05:05 PM
Weinhoff Gregory M	Officer	Mar 13 '26	Proposed Sale	27.23	73,196	1,993,493		Mar 13 04:09 PM
HUSSAIN IQBAL J	Chief Legal Officer	Feb 02 '26	Sale	25.15	38,951	979,657	57,645	Feb 03 06:59 PM
HUSSAIN IQBAL J	Chief Legal Officer	Jan 30 '26	Sale	25.01	1,010	25,261	104,376	Feb 03 06:59 PM
Iqbal Hussain	Officer	Jan 30 '26	Proposed Sale	25.50	39,961	1,019,005		Jan 30 04:29 PM
Saurabh Saha	Former Officer	Jan 21 '26	Proposed Sale	22.87	2,300,000	52,601,000		Jan 21 04:58 PM
Saurabh Saha	Previous Officer	Jan 02 '26	Proposed Sale	24.30	2,500,000	60,750,000		Jan 02 04:45 PM
Accardi Mario Alberto	President, Orexin Program	Dec 09 '25	Sale	28.83	10,000	288,289	178,801	Dec 09 07:07 PM
Accardi Mario Alberto	Officer	Dec 09 '25	Proposed Sale	29.30	10,000	293,000		Dec 09 04:39 PM
Accardi Mario Alberto	President, Orexin Program	Dec 08 '25	Option Exercise	9.53	5,000	47,650	198,801	Dec 08 06:26 PM
Accardi Mario Alberto	President, Orexin Program	Dec 08 '25	Sale	30.00	10,000	300,000	188,801	Dec 08 06:26 PM
Accardi Mario Alberto	Officer	Dec 08 '25	Proposed Sale	30.00	10,000	300,000		Dec 08 04:06 PM
HUSSAIN IQBAL J	General Counsel	Nov 17 '25	Option Exercise	5.84	6,000	35,040	111,386	Nov 18 04:18 PM
HUSSAIN IQBAL J	General Counsel	Nov 17 '25	Sale	27.64	6,000	165,835	105,386	Nov 18 04:18 PM
Bush Tia L	Chief Technology & Quality Ofc	Nov 17 '25	Option Exercise	9.42	40,000	376,800	161,503	Nov 18 04:17 PM
Bush Tia L	Chief Technology & Quality Ofc	Nov 17 '25	Sale	28.00	40,000	1,120,000	121,503	Nov 18 04:17 PM
Bush Tia L	Officer	Nov 17 '25	Proposed Sale	28.00	40,000	1,120,000		Nov 17 04:03 PM
HUSSAIN IQBAL J	Officer	Nov 17 '25	Proposed Sale	27.74	6,000	166,440		Nov 17 04:01 PM
Bush Tia L	Chief Technology & Quality Ofc	Nov 12 '25	Option Exercise	9.42	40,000	376,800	161,503	Nov 13 05:02 PM
Bush Tia L	Chief Technology & Quality Ofc	Nov 12 '25	Sale	26.00	40,000	1,040,000	121,503	Nov 13 05:02 PM
Bush Tia L	Officer	Nov 12 '25	Proposed Sale	26.00	40,000	1,040,000		Nov 12 04:05 PM
Accardi Mario Alberto	President, Orexin Program	Oct 27 '25	Option Exercise	8.01	5,000	40,050	202,394	Oct 27 07:56 PM
Accardi Mario Alberto	President, Orexin Program	Oct 27 '25	Sale	25.00	8,000	200,000	194,394	Oct 27 07:56 PM
Accardi Mario Alberto	Officer	Oct 27 '25	Proposed Sale	25.00	8,000	200,000		Oct 27 04:01 PM
HUSSAIN IQBAL J	General Counsel	Oct 15 '25	Option Exercise	5.84	6,000	35,040	111,386	Oct 16 04:13 PM
HUSSAIN IQBAL J	General Counsel	Oct 15 '25	Sale	22.41	6,000	134,439	105,386	Oct 16 04:13 PM
HUSSAIN IQBAL J	Officer	Oct 15 '25	Proposed Sale	22.61	6,000	135,660		Oct 15 04:17 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 24 '25	Option Exercise	9.42	35,000	329,700	156,503	Sep 24 07:00 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 24 '25	Sale	24.00	35,000	840,000	121,503	Sep 24 07:00 PM
Bush Tia L	Officer	Sep 24 '25	Proposed Sale	24.00	35,000	840,000		Sep 24 04:00 PM
Accardi Mario Alberto	President, Orexin Program	Sep 16 '25	Sale	21.40	8,172	174,846	197,394	Sep 16 06:16 PM
Accardi Mario Alberto	Officer	Sep 16 '25	Proposed Sale	22.06	8,172	180,274		Sep 16 04:09 PM
HUSSAIN IQBAL J	General Counsel	Sep 15 '25	Option Exercise	5.84	6,000	35,040	111,386	Sep 15 06:37 PM
HUSSAIN IQBAL J	General Counsel	Sep 15 '25	Sale	21.85	6,000	131,101	105,386	Sep 15 06:37 PM
HUSSAIN IQBAL J	Officer	Sep 15 '25	Proposed Sale	21.81	6,000	130,860		Sep 15 04:09 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 10 '25	Option Exercise	9.42	25,000	235,500	146,503	Sep 11 05:50 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 09 '25	Option Exercise	8.01	24,792	198,584	146,295	Sep 11 05:50 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 10 '25	Sale	22.00	25,000	550,000	121,503	Sep 11 05:50 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 09 '25	Sale	20.00	24,792	495,840	121,503	Sep 11 05:50 PM
HUSSAIN IQBAL J	General Counsel	Sep 09 '25	Option Exercise	5.84	20,000	116,800	125,386	Sep 11 05:47 PM
HUSSAIN IQBAL J	General Counsel	Sep 10 '25	Option Exercise	5.84	20,000	116,800	125,386	Sep 11 05:47 PM
HUSSAIN IQBAL J	General Counsel	Sep 10 '25	Sale	22.00	20,000	440,000	105,386	Sep 11 05:47 PM
HUSSAIN IQBAL J	General Counsel	Sep 09 '25	Sale	20.01	20,000	400,102	105,386	Sep 11 05:47 PM
Accardi Mario Alberto	President, Orexin Program	Sep 09 '25	Option Exercise	8.01	5,000	40,050	212,566	Sep 11 05:45 PM
Accardi Mario Alberto	President, Orexin Program	Sep 09 '25	Sale	20.00	7,000	140,000	205,566	Sep 11 05:45 PM
Bush Tia L	Officer	Sep 10 '25	Proposed Sale	22.00	25,000	550,000		Sep 10 04:17 PM
HUSSAIN IQBAL J	Officer	Sep 10 '25	Proposed Sale	22.00	20,000	440,000		Sep 10 04:09 PM
Bush Tia L	Officer	Sep 09 '25	Proposed Sale	20.00	24,792	495,840		Sep 09 04:04 PM
Accardi Mario Alberto	Officer	Sep 09 '25	Proposed Sale	20.00	7,000	140,000		Sep 09 04:04 PM
HUSSAIN IQBAL J	Officer	Sep 09 '25	Proposed Sale	20.01	20,000	400,102		Sep 09 04:03 PM
HUSSAIN IQBAL J	General Counsel	Aug 15 '25	Option Exercise	5.84	6,000	35,040	111,386	Aug 15 06:13 PM
HUSSAIN IQBAL J	General Counsel	Aug 15 '25	Sale	17.23	6,000	103,380	105,386	Aug 15 06:13 PM
HUSSAIN IQBAL J	Officer	Aug 15 '25	Proposed Sale	17.23	6,000	103,380		Aug 15 04:03 PM
Accardi Mario Alberto	President, Orexin Program	Jul 29 '25	Sale	15.23	8,322	126,751	208,163	Jul 30 05:00 PM
Accardi Mario Alberto	Officer	Jul 29 '25	Proposed Sale	15.37	8,322	127,909		Jul 29 04:53 PM
Weinhoff Gregory M	Chief Business Officer	Jul 25 '25	Option Exercise	3.85	10,000	38,500	132,279	Jul 25 06:24 PM
Weinhoff Gregory M	Chief Business Officer	Jul 25 '25	Sale	15.56	10,000	155,598	122,279	Jul 25 06:24 PM
Weinhoff Gregory M	Officer	Jul 25 '25	Proposed Sale	15.56	10,000	155,598		Jul 25 04:05 PM
SAHA SAURABH	Chief Executive Officer	Jul 21 '25	Option Exercise	3.85	55,000	211,750	276,017	Jul 21 07:39 PM
SAHA SAURABH	Chief Executive Officer	Jul 21 '25	Sale	15.92	55,000	875,600	221,017	Jul 21 07:39 PM
SAHA SAURABH	Officer	Jul 21 '25	Proposed Sale	15.99	55,000	879,450		Jul 21 04:01 PM
CHAO DAVID M	Officer	Jul 17 '25	Proposed Sale	16.00	5,000	80,000		Jul 17 05:17 PM
CHAO DAVID M	Officer	Jul 15 '25	Proposed Sale	14.92	10,000	149,182		Jul 17 05:15 PM
HUSSAIN IQBAL J	General Counsel	Jul 15 '25	Option Exercise	5.84	6,000	35,040	111,386	Jul 17 04:15 PM
HUSSAIN IQBAL J	General Counsel	Jul 15 '25	Sale	14.93	6,000	89,567	105,386	Jul 17 04:15 PM
HUSSAIN IQBAL J	Officer	Jul 15 '25	Proposed Sale	14.93	6,000	89,567		Jul 15 04:04 PM
Weinhoff Gregory M	Chief Business Officer	Jun 25 '25	Option Exercise	3.85	10,000	38,500	132,279	Jun 25 07:44 PM
Weinhoff Gregory M	Chief Business Officer	Jun 25 '25	Sale	13.86	10,000	138,642	122,279	Jun 25 07:44 PM
HUSSAIN IQBAL J	General Counsel	Jun 24 '25	Option Exercise	5.84	12,000	70,080	117,386	Jun 25 07:43 PM
HUSSAIN IQBAL J	General Counsel	Jun 24 '25	Sale	14.02	12,000	168,218	105,386	Jun 25 07:43 PM
Accardi Mario Alberto	President, Orexin Program	Jun 24 '25	Option Exercise	3.85	15,000	57,750	231,485	Jun 25 07:42 PM
Accardi Mario Alberto	President, Orexin Program	Jun 24 '25	Sale	14.00	15,000	210,000	216,485	Jun 25 07:42 PM
Weinhoff Gregory M	Officer	Jun 25 '25	Proposed Sale	14.00	10,000	140,000		Jun 25 04:06 PM
Accardi Mario Alberto	Officer	Jun 24 '25	Proposed Sale	14.00	15,000	210,000		Jun 25 01:54 PM
HUSSAIN IQBAL J	Officer	Jun 24 '25	Proposed Sale	14.02	12,000	168,218		Jun 24 04:09 PM
SAHA SAURABH	Chief Executive Officer	Jun 20 '25	Option Exercise	3.85	55,000	211,750	276,017	Jun 20 08:58 PM
SAHA SAURABH	Chief Executive Officer	Jun 20 '25	Sale	12.63	55,000	694,826	221,017	Jun 20 08:58 PM
CHAO DAVID M	Officer	Jun 20 '25	Proposed Sale	12.87	10,000	128,650		Jun 20 04:14 PM
SAHA SAURABH	Officer	Jun 20 '25	Proposed Sale	12.87	55,000	707,575		Jun 20 04:14 PM
Weinhoff Gregory M	Chief Business Officer	May 27 '25	Option Exercise	3.85	10,000	38,500	132,279	May 27 06:31 PM
Weinhoff Gregory M	Chief Business Officer	May 27 '25	Sale	12.82	10,000	128,225	122,279	May 27 06:31 PM
Weinhoff Gregory M	Officer	May 27 '25	Proposed Sale	12.82	10,000	128,225		May 27 04:02 PM
SAHA SAURABH	Chief Executive Officer	May 20 '25	Option Exercise	3.85	55,000	211,750	276,017	May 20 05:44 PM
SAHA SAURABH	Chief Executive Officer	May 20 '25	Sale	12.71	55,000	699,110	221,017	May 20 05:44 PM
SAHA SAURABH	Officer	May 20 '25	Proposed Sale	12.74	55,000	700,700		May 20 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNTA

Centessa Pharmaceuticals plc ADR

Upgrade your Finviz experience